fesoterodine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4191 286930-02-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fesoterodine
  • toviaz
  • fesoterodine fumarate
a muscarinic antagonist for treatment of overactive bladder
  • Molecular weight: 411.59
  • Formula: C26H37NO3
  • CLOGP: 4.36
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.77
  • ALOGS: -5.30
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O
3.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 256 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.33 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 2008 FDA PFIZER
April 20, 2007 EMA Pfizer Europe MA EEIG
Dec. 25, 2012 PMDA PFIZER JAPAN INC.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 252.06 16.81 107 8054 30194 63450667
Dry mouth 219.40 16.81 132 8029 77731 63403130
Brain injury 105.00 16.81 38 8123 7005 63473856
Fall 95.39 16.81 176 7985 392158 63088703
Pulseless electrical activity 77.52 16.81 31 8130 7490 63473371
Urinary incontinence 74.15 16.81 48 8113 31966 63448895
Multiple fractures 73.44 16.81 31 8130 8587 63472274
Electrocardiogram QRS complex prolonged 63.02 16.81 25 8136 5913 63474948
Catarrh 54.40 16.81 16 8145 1533 63479328
Dysuria 48.88 16.81 38 8123 33700 63447161
Steroid dependence 48.12 16.81 15 8146 1749 63479112
Burns second degree 46.43 16.81 15 8146 1963 63478898
Colitis ulcerative 39.13 16.81 30 8131 26061 63454800
Hypopnoea 36.85 16.81 15 8146 3791 63477070
Gait disturbance 36.77 16.81 76 8085 183102 63297759
Frequent bowel movements 35.69 16.81 27 8134 22995 63457866
Bradycardia 34.90 16.81 45 8116 73182 63407679
Constipation 34.69 16.81 84 8077 224859 63256002
Gingival pain 34.23 16.81 18 8143 8144 63472717
Vertigo 32.04 16.81 39 8122 59848 63421013
Nocturia 28.70 16.81 16 8145 8125 63472736
Bladder spasm 27.97 16.81 10 8151 1778 63479083
Tubulointerstitial nephritis 27.92 16.81 22 8139 19881 63460980
Micturition urgency 26.23 16.81 16 8145 9595 63471266
Dry throat 25.78 16.81 14 8147 6751 63474110
Loss of consciousness 24.85 16.81 50 8111 118071 63362790
Rectal haemorrhage 24.73 16.81 31 8130 48999 63431862
Swollen tongue 24.26 16.81 26 8135 34774 63446087
Parosmia 24.09 16.81 13 8148 6193 63474668
Tinnitus 23.76 16.81 26 8135 35602 63445259
Stress 22.67 16.81 35 8126 67132 63413729
Rhinitis 21.41 16.81 15 8146 11351 63469510
Impaired quality of life 21.00 16.81 16 8145 13767 63467094
Product blister packaging issue 20.77 16.81 5 8156 221 63480640
Therapeutic product effect incomplete 20.65 16.81 48 8113 125008 63355853
Feeling abnormal 20.31 16.81 53 8108 148339 63332522
Nightmare 20.25 16.81 18 8143 19176 63461685
Cardiac murmur 20.23 16.81 16 8145 14536 63466325
Overdose 18.81 16.81 44 8117 115034 63365827
Bronchiectasis 18.77 16.81 16 8145 16126 63464735
Anticholinergic syndrome 18.41 16.81 8 8153 2374 63478487
Palpitations 18.30 16.81 43 8118 112727 63368134
Pollakiuria 17.95 16.81 20 8141 27917 63452944
Multiple sclerosis relapse 17.40 16.81 26 8135 48452 63432409
Vision blurred 17.09 16.81 37 8124 91887 63388974
Balance disorder 16.87 16.81 35 8126 84387 63396474

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 415.46 21.92 149 3249 36139 34917394
Dry mouth 106.63 21.92 54 3344 30111 34923422
Dysuria 48.13 21.92 31 3367 27121 34926412
Fall 41.37 21.92 72 3326 202813 34750720
Catarrh 41.11 21.92 11 3387 991 34952542
Burns second degree 39.81 21.92 11 3387 1118 34952415
Steroid dependence 36.60 21.92 11 3387 1506 34952027
Hypertonic bladder 34.37 21.92 11 3387 1853 34951680
Dementia 32.82 21.92 19 3379 13729 34939804
Gingival pain 32.72 21.92 12 3386 3040 34950493
Hypopnoea 32.15 21.92 11 3387 2278 34951255
Parosmia 31.53 21.92 11 3387 2414 34951119
Benign prostatic hyperplasia 29.31 21.92 18 3380 14477 34939056
Cystitis interstitial 29.22 21.92 6 3392 169 34953364
Systemic lupus erythematosus 26.93 21.92 11 3387 3713 34949820
Swollen tongue 26.66 21.92 17 3381 14588 34938945
Confusional state 26.53 21.92 49 3349 144111 34809422
Vertigo 22.19 21.92 19 3379 25517 34928016

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 308.05 16.71 146 9533 56484 79678225
Dry mouth 191.35 16.71 124 9555 87895 79646814
Fall 124.10 16.71 216 9463 487413 79247296
Brain injury 88.97 16.71 38 9641 11479 79723230
Catarrh 80.01 16.71 23 9656 2155 79732554
Multiple fractures 77.29 16.71 31 9648 7995 79726714
Burns second degree 71.48 16.71 22 9657 2606 79732103
Steroid dependence 71.47 16.71 22 9657 2608 79732101
Pulseless electrical activity 66.28 16.71 33 9646 14127 79720582
Urinary incontinence 59.24 16.71 45 9634 40864 79693845
Gingival pain 57.54 16.71 26 9653 8972 79725737
Hypopnoea 56.26 16.71 22 9657 5307 79729402
Dysuria 54.59 16.71 47 9632 50904 79683805
Parosmia 50.42 16.71 22 9657 6992 79727717
Vertigo 47.75 16.71 50 9629 69032 79665677
Electrocardiogram QRS complex prolonged 47.05 16.71 24 9655 10809 79723900
Colitis ulcerative 45.47 16.71 36 9643 34706 79700003
Frequent bowel movements 43.88 16.71 33 9646 29506 79705203
Swollen tongue 39.10 16.71 36 9643 42534 79692175
Gait disturbance 38.97 16.71 81 9598 207425 79527284
Rectal haemorrhage 37.06 16.71 46 9633 76254 79658455
Hypertonic bladder 36.25 16.71 15 9664 4186 79730523
Cardiac murmur 36.05 16.71 23 9656 15801 79718908
Impaired quality of life 35.51 16.71 22 9657 14364 79720345
Rhinitis 34.92 16.71 22 9657 14785 79719924
Nightmare 30.04 16.71 25 9654 25836 79708873
Urinary tract infection 29.01 16.71 86 9593 274426 79460283
Bronchiectasis 28.87 16.71 23 9656 22363 79712346
Cystitis interstitial 27.01 16.71 9 9670 1374 79733335
Tinnitus 25.26 16.71 29 9650 44304 79690405
Stress 25.12 16.71 39 9640 79573 79655136
Impaired work ability 24.90 16.71 20 9659 19661 79715048
Dementia 24.90 16.71 22 9657 24637 79710072
Benign prostatic hyperplasia 24.29 16.71 16 9663 11596 79723113
Nocturia 24.22 16.71 17 9662 13664 79721045
Therapeutic product effect incomplete 23.93 16.71 53 9626 141592 79593117
Constipation 23.81 16.71 82 9597 282968 79451741
Tubulointerstitial nephritis 23.47 16.71 26 9653 38209 79696500
Confusional state 23.25 16.71 88 9591 317909 79416800
Micturition urgency 23.06 16.71 16 9663 12625 79722084
Bladder spasm 22.38 16.71 9 9670 2334 79732375
Loss of consciousness 22.07 16.71 57 9622 167886 79566823
Toxicity to various agents 21.84 16.71 12 9667 421528 79313181
Accidental overdose 21.06 16.71 25 9654 39556 79695153
Product blister packaging issue 20.97 16.71 5 9674 225 79734484
Body height decreased 20.87 16.71 13 9666 8567 79726142
Drug ineffective 20.79 16.71 211 9468 1080702 78654007
Urine flow decreased 20.72 16.71 7 9672 1114 79733595
Completed suicide 19.98 16.71 3 9676 245764 79488945
Bradycardia 19.90 16.71 48 9631 135509 79599200
Intentional product use issue 19.34 16.71 51 9628 152061 79582648
Palpitations 18.76 16.71 45 9634 126565 79608144
Cystitis 18.29 16.71 27 9652 52705 79682004
Colitis ischaemic 18.15 16.71 15 9664 15344 79719365
Bladder disorder 17.66 16.71 12 9667 9153 79725556
Eczema 17.28 16.71 23 9656 40795 79693914
Arthritis 17.20 16.71 41 9638 114839 79619870
Product prescribing error 17.08 16.71 24 9655 44789 79689920
Medication error 16.79 16.71 30 9649 68612 79666097

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD11 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
ATC G04BD13 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Increased Urinary Frequency indication
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Myasthenia gravis contraindication 91637004 DOID:437
Acute constipation contraindication 197119006
Bladder outflow obstruction contraindication 236645006
Retention of urine contraindication 267064002
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastrointestinal hypomotility contraindication 421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Aggravated Glaucoma contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.64 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 7807715 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
4MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 8088398 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
8MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 7807715 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
8MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 8088398 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
4MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL June 17, 2024 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG
8MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL June 17, 2024 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG
4MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL Dec. 17, 2024 PEDIATRIC EXCLUSIVITY
8MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL Dec. 17, 2024 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 6.40 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 6.27 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 6.39 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 6.19 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 5.98 WOMBAT-PK

External reference:

IDSource
4028101 VUID
N0000179802 NUI
D07226 KEGG_DRUG
286930-03-8 SECONDARY_CAS_RN
4028101 VANDF
4028102 VANDF
C2343853 UMLSCUI
CHEBI:135920 CHEBI
CHEMBL1201764 ChEMBL_ID
CHEMBL1201765 ChEMBL_ID
DB06702 DRUGBANK_ID
C526675 MESH_SUPPLEMENTAL_RECORD_UI
7473 IUPHAR_LIGAND_ID
8068 INN_ID
621G617227 UNII
6918558 PUBCHEM_CID
DB15578 DRUGBANK_ID
797195 RXNORM
137285 MMSL
25992 MMSL
358891 MMSL
d07162 MMSL
012671 NDDF
012672 NDDF
432254002 SNOMEDCT_US
432255001 SNOMEDCT_US
441469003 SNOMEDCT_US
C4301611 UMLSCUI
CHEMBL3348932 ChEMBL_ID
10020 INN_ID
207679-81-0 SECONDARY_CAS_RN
9819382 PUBCHEM_CID
YU871O78GR UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0244 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0244 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0244 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 32 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 43598-247 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 43598-248 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 26 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 46708-175 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 46708-176 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 27 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 51407-661 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 51407-662 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 26 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 54868-6156 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 29 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 54868-6175 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 29 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 62332-175 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 62332-176 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 27 sections
Fesoterodine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 62559-376 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 28 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 63539-183 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 63539-183 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 63539-242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 32 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 63539-242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 32 sections
Fesoterodine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 65162-369 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
Fesoterodine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 65162-370 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 20 sections
FESOTERODINE FUMARATE Human Prescription Drug Label 1 65862-766 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
FESOTERODINE FUMARATE Human Prescription Drug Label 1 65862-766 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
FESOTERODINE FUMARATE Human Prescription Drug Label 1 65862-767 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 27 sections
FESOTERODINE FUMARATE Human Prescription Drug Label 1 65862-767 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 27 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 67877-064 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 67877-068 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 26 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 68180-618 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections